An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection would significantly reduce the global burden of disease associated with chronic HCV infection.Expand abstract
A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime/boost regimen induc...
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Copyright holder:
- Swadling et al.
- Copyright date:
- © 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license.
Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
If you are the owner of this record, you can report an update to it here: Report update to this record